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126 Poster Session-IIAcute GVHD following sibling RIC transplants was analyzed in
110 patients (63 males; 47 females) with a median age of 46.5 years
(17263) transplanted between 1998 and 2008 for various malignant
and non-malignant indications. Fludarabine [120–150 mg/m2] with
either Cyclophosphamide [120 mg/kg] (n 5 87), Melphalan [140
mg/m2] (n 5 15), oral Busulfan [10 mg/kg] (n 5 6) or Cytosine ara-
binoside (n 5 2) was used for conditioning with peripheral blood
stem cells (PBSC) as graft source. GVHD prophylaxis included Cy-
closporine either alone [n5 19] or with low dose methotrexate [n5
53] or mycophenolate [n 5 38]. Nine patients received Antithymo-
cyte globulin (ATG) in addition. A median of 5.7  106 CD34/kg
(0.96218.9) cells was infused with a median neutrophil and platelet
recovery of 14 (5 – 33) and 17 days (0 – 157) respectively. Acute
GVHD occurred in 66 (60%) at a median of 29 days (12 – 86)
with grade II-IV GVHD in 46.3% and grade III– IV in 20.9%. Seven
patients (10.6%) died due to either acute GVHD or infection.
Chronic GVHD occurred in 56% of evaluable patients. At a median
of 28 months (range: 2 – 105), overall survival (OS) is 47.2% with an
OS of 43.9% with GVHD and 52.2% without GVHD (p5 0.434). A
number of variables were analysed including recipient and donor age
and gender, ABO incompatibility, conditioning regimen, GVHD
prophylaxis, use of ATG, cell dose, time to neutrophil recovery
and Absolute lymphocyte count (ALC) on day 15 and day 30 post
transplant. On univariate analysis, donor age (p5 0.015), neutrophil
recovery\ 15 days (p 5 0.013), Day 15 ALC . 0.6  109/L (p 5
0.038) and sex mismatched transplant (p 5 0.018) were identified
as risk factors for GVHD while diagnosis of AML (p 5 0.001), use
of Flu/Bu (p 5 0.033) and presence of major ABO incompatibility
(p 5 0.039) were risk factors identified as protective. On a multiple
logistic regression analysis (Table 1), donor age and sex mismatched
transplant continued to remain significant while Flu/Bu condition-
ing, diagnosis of AML and major ABO incompatibility remained
protective. A better understanding of the risk factors causing
GVHD will help in establishing better regimens for conditioning
and GVHD prophylaxis leading to improved survival with RIC
regimens.
Multivariate proportional hazard regression analysis of all pa-
tients
Variable Relative risk Confidence interval p valueDonor age 1.051 1.010 – 1.094 0.015
Sex mismatch 3.874 1.260 – 11.915 0.018
Diagnosis of AML 0.202 0.077 – 0.531 0.001
Flu/Bu conditioning 0.071 0.006 – 0.805 0.033
ABO major mismatch 0.206 0.070 – 0.934 0.039351
INTENSIVE EXTRA CORPOREAL PHOTOTHERAPY (ECP) COURSES IN
ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) PATIENTS
Tassi, C., Giudice, V., Baldazzi, P., Guizzardi, A.M., Rago, E., Vitali, P.,
Zimotti, A., Pagliaro, P. Unita` Operativa di Immunoematologia e Tras-
fusionale, Bologna, Italy
AGVHD may occur in a high proportion of allo-transplanted pa-
tients and is one the main causes of death. ECP treatment may suc-
cessfully be employed in patients refractory or not eligible to high
doses steroid therapy. The ECP intensification, as well as the timely
start of the courses, are probably fundamental to enhance the prob-
ability and the rate of clinical response. Ten aGVHD III-IV patients,
7 males and 3 females, were enrolled. Four were adults and six were
children with liver, gut or skin localization. The mean time from
aGVHD diagnosis to ECP starting was seven days. Three ECP
were performed weekly for three consecutive weeks then two proce-
dures every two weeks were carried out in six months. A mean of 16
(6–29) procedures per patient was carried out, being 4 (1–6) months
the mean duration per treatment. Phenotype studies disclosed Treg
cells and circulating oligoclonal TCRVB subsets in in two and five
patients, respectively. Cyclosporine A was used as primary immuno-
suppressive drug in six patients or associated to MMF or tacrolimus
in two and one patients. One patient received MMF alone and four,
Infliximab (3–6 doses). Two patients died for progressive GVHDand in one ECP was stopped for severe CMV reactivation. Seven pa-
tients (78%) had fast and significant clinical recovery after the first
six, intensified ECP and the mean follow-up observed is of 29 (6–
50) months. One child responsive after seven ECP courses died for
acute liver failure, one month after the ECP had been concluded
One child relapsed and died for NB in the first year post transplan-
tation, two adults are alive with relapsed HL, the others are alive
without clinical or molecular signs of relapse. As regards phenotype
studies, in two responsive patients, not treated with Cyclosporine A,
Treg absolute counts tripled during ECP treatment while oligoclo-
nal TCRVB families disappeared in all responsive patients. Despite
the limited number of the subjects treated, the rapid clinical recovery
observed in these highly compromised patients enforces the indica-
tion to employ intensive ECP courses to accelerate the clinical re-
mission and to reduce the immunosuppression. As regards the
possible use of the Treg or the TCRVB oligoclonal subsets modifi-
cations as prognostic factors during ECP treatment, the true involve-
ment of these subpopulations is up to date, unclear. In particular
Cyclosporine A might inhibit the production of Tregs and probably,
other biological markers must be individuated.352
FASL, PERFORIN, AND TRAIL ARE NOT REQUIRED BY T CELL S FOR EP-
ITHELIAL DAMAGE IN A CUTANEOUS GVHD-LIKE REACTION ACROSS MI-
NOR HISTOCOMPATIBILITY ANTIGENS IN VITRO
Arditti, F.D., Goldgirsh, K., Friedman, T., Korngold, R. Hackensack Uni-
versity Medical Center, Hackensack, NJ
The role of Fas Ligand (FasL), Perforin, and TRAIL during the
immunopathological development of graft-versus-host disease
(GVHD) remains unclear. We utilized a recently established culture
system to pinpoint their role in mediating a cutaneous GVHD-like
reaction across minor histocompatibility antigens (miHA) by either
CD41 or CD81 T cell subsets. Despite the upregulation (27 6
3.2 to 43 6 5.1 MFI) of Fas on primary skin epithelial cells (pEC)
cocultured with T cells, FasL deficient B6Smn.C3H-Faslgld (Gld)
T cells killed C.B10-H2b (BALB.B) pEC as efficiently as normal
C57Bl/6 (B6) T cells (p . 0.5), suggesting that a FasL-independent
mechanism is active. Interferon gamma (IFN-g) was secreted by
both CD41 and CD81 separated normal T cell subsets, and they
were able to upregulate the expression of H2Kb. However, unsepa-
rated T cells induced more potent effects than either individual
CD41 (p\0.03) or CD81 (p\0.04) subset. The presence of IFN-
g had no effect on Fas expression, also consistent with the lack of
any such observable effect with the addition of recombinant IFN-g
to the cultures. By day 5 of incubation of pEC with Perforin-defi-
cient CD41 T cells, no dead cells were detected in the epithelial
layer, as compared with the onset of cytotoxicity already elicited by
normal, GLD, or TRAIL-deficient CD41 T cells. However, this
decreased reactivity of Perforin-deficient CD41 T cells was not
long lasting and was subsequently replaced by a less potent but still
efficient cytotoxic effect, as compared with that induced by normal
(p\ 0.002), FasL (p\ 0.02) or TRAIL-deficient (p\0.04) CD41
T cells. TRAIL-deficient T cells secreted higher amounts of
IFN-g.; but the CD81 TRAIL-deficient subset exhibited lowered
cytotoxicity against pEC. As found with T cells deficient in FasL
and Perforin, TRAIL-deficiency did not prevent the cytotoxic effect.
In summary, our results suggest that Fas-FasL, TRAIL and Perforin
are indeed involved in T cell mediated GVHD-like effects against
pEC, although neither of them are essential to severely damage the
epithelial cells. Rather, a key role for other known, as well as un-
known, cytotoxic pathways are indicated and should be examined.353
BORTEZOMIB TREATMENT OF PRIMITIVE QUIESCENT CD341 CELL S IN
CHRONIC MYELOID LEUKEMIA ENHANCES TARGETING BY IN VITRO EX-
PANDED ALLOGENEIC NATURAL KILLER CELL S
Yong, A.S.M.1, Keyvanfar, K.1, Hensel, N.1, Eniafe, R.1, Savani, B.N.2,
Berg, M.1, Lundqvist, A.1, Adams, S.1, Sloand, E.M.1, Goldman, J.M.3,
Childs, R.1, Barrett, A.J.1 1 National Heart, Lung and Blood Institute,
National Institutes of Health, Bethesda, MD; 2 Vanderbilt University
and VAMC Transplant Program, Nashville, TN; 3 Imperial College Lon-
don, Hammersmith Hospital, London, United Kingdom
Poster Session-II 127Primitive quiescent CD341 cells in chronic myeloid leukemia
(CML) are relatively resistant to tyrosine kinase inhibitors, which
may explain the persistence of detectable BCR-ABL transcripts fol-
lowing treatment with these agents. Conversely, allogeneic stem
cell transplantation (SCT) can eradicate residual CML, suggesting
that quiescent stem cells are eliminated by graft-versus-leukemia
(GVL) effects. We studied the progeny of CD341 cells after 4
days culture in serum-free media supplemented with interleukin-3,
interleukin-6, stem cell factor, granulocyte-colony stimulating factor
and Flt-3 ligand in 14 CML patients who subsequently received T
cell depleted SCT from their HLA-identical sibling donors. Cycling
CD34-negative and CD341, and non-cycling quiescent CD341
CML cells were isolated by fluorescence activated cell sorting. Fluo-
rescence in situ hybridization in 7 representative CML patients re-
vealed over 80% BCR-ABL positivity in both quiescent and
cycling CD341 and CD34-negative populations. The expression
of BCR-ABL was the same in both cycling and quiescent CD341
cell populations. Quiescent CD341 cells from CML patients were
lysed by natural killer (NK) cells from their donors, which had
been expanded after 11–13 days culture with interleukin-2 and irra-
diated EBV-LCL. Quiescent CD341 cells were less susceptible than
their cycling CD341 and CD34-negative counterparts to NK cyto-
toxicity. Compared to cycling populations, quiescent CD341 cells
from CML patients had higher expression of tumor necrosis fac-
tor-related apoptosis-inducing ligand (TRAIL) receptors. Previous
studies have demonstrated that bortezomib can sensitize malignant
cells to NK-cell TRAIL (Lundqvist et al Cancer Res 2006). Bortezo-
mib treatment of quiescent CD341 CML cells enhanced their kill-
ing by expanded donor NK cells. This increased sensitivity to NK-
cytotoxicity correlated with upregulation of TRAIL receptor DR4
on the surface of quiescent CD341 CML cells. Bortezomib did
not significantly affect the expression of MHC Class I, MIC A/B
or Fas (CD95) on CD341 quiescent or cycling cells. These results
suggest that adoptive transfer of in vitro expanded donor NK cells
with concomitant administration of bortezomib to the recipient
may enhance cytotoxicity to quiescent CD341 cells and may im-
prove NK-mediated GVL effects. This may be particularly applica-
ble to CML patients who are transplanted in more advanced stage
disease, and are at a greater risk of relapse.354
DISMAL RESPONSE TO HIGH DOSE METHYLPREDNISOLONE (MP) AFTER
FAILURE TO RESPOND TO STANDARD DOSE IN PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT) PATIENTS WITH ACUTE
GRAFT-VERSUS-HOST-DISEASE (AGVHD)
Schechter, T.1, McCartney, C.1, Finkelstein, Y.2,3, Gassas, A.1, Doyle, J.1,
Dupuis, L.1 1 The Hospital for Sick Children, Toronto, ON, Canada;
2 Children’s Hospital, Boston, MA; 3 The Hospital for SicK Children, Tor-
onto, ON, Canada
Introduction: Corticosteroids remain the primary therapy for
aGVHD. The reported response rate to standard treatment (IV
MP 2mg/kg/day for 14 days then tapered) is 70%. Patients who
are refractory to standard treatment may be treated with high dose
MP. We evaluated the response to high dose MP in children with
aGVHD refractory to standard dose MP.
Methods: Children included in this evaluation underwent HSCT
between June 1, 2002 and July 31, 2006; did not receive MP for
aGVHD prophylaxis; developed $ grade II aGVHD; and received
MP 2mg/kg/day as initial therapy. Response to aGVHD therapy, al-
ternate aGVHD treatment, adverse effects attributed to MP and
overall outcomes were documented.
Results: 50 children (29 male; mean age 8.9yrs (range 0.3–17yrs))
developed aGVHD during the study period. The median time to di-
agnosis of aGVHD $ grade II was 18 days (range 10–60 days). 34
children had single organ involvement alone; 36 (72%) responded
to standard dose MP including 29 of 34 children with aGVHD in-
volving a single organ. Of the 14 children who failed to respond to
standard treatment, 12 children received high dose MP ($20mg/
kg/day) for 3 consecutive days followed by tapering dose. When
high dose MP was started, 10 patients had skin, 8 gut, 7 liver and 1
lung aGVHD. 11 patients had $ grade III aGVHD when high
dose MP was started. 10 patients received high dose MP at a median
of 11 days (range 3–18days) after starting standard treatment while 2patients received high dose MP after other non-steroid therapy failed.
Only one patient with grade III aGVHD (stage 3 skin, stage 2 liver)
had complete response. 2 patients had partial response but flared
when MP was tapered. All patients who failed high dose MP needed
further salvage therapy. All children who received MP developed hy-
pertension and required antihypertensive medication. 16 children de-
veloped hyperglycemia (7 on high dose MP); 5 required insulin.
While on high-dose or tapering of high-dose MP, 5 developed severe
infection (2 fungal, 2 adenovirus, 1 bacterial). 22 out of the 36 patients
who responded to standard treatment were available for follow-up; 13
(60%) are alive (median follow-up:39mos). 6 children (50%) who re-
ceived high dose MP therapy died (median follow-up:46mos).
Conclusions: Children with aGVHD refractory to standard dose
MP who subsequently receive high dose MP do not respond and ex-
perience significant adverse effects. Other salvage therapy should be
considered in these patients.355
N-ACETYL-L-CYSTEINE PROMOTES T CELL MEDIATED
IMMUNITY IN ALLOGENEIC SETTINGS IN VIVO AND
IN VITRO
Karlsson, H.1,2, Nava, S.1, Remberger, M.1,2, Hassan, Z.2, Hassan, M.3,
Ringden, O.1,2 1 Karolinska Institutet, Stockholm, Sweden; 2 Karolinska
University Hopstial Huddinge, Stockholm, Sweden; 3 Karolinska Institu-
tet, Stockholm, Sweden
N-acetyl-L-cysteine (NAC) is a thiol antioxidant which stimulates
glutathione synthesis in cells. Several studies indicate that NAC ex-
erts effects on the immune system in vitro, although with conflicting
results. Whereas some studies indicate that NAC has an inhibitory
effect on T cell proliferation and activation of NF-kB, others suggest
an activating effect. The ability of NAC to protect cells against oxi-
dative stress by inducing glutathione has provided a rationale for us-
ing it to prevent veno-occlusive disease of the liver and liver toxicity
after allogeneic stem cell transplantation (ASCT). Unfortunately,
a prospective randomized study failed to show a positive effect of
NAC on hepatotoxicity in ASCT patients. However, we observed
that patients who received NAC as a therapy to treat liver toxicity
(n 5 73) had an increased prevalence of acute GvHD compared to
patients who had been randomized to not receive NAC (n 5 87)
(P 5 0.04), indicating that NAC has an immunostimulatory effect
in vivo. Importantly, the NAC-treated group only had an increased
risk of grade II acute GvHD (30%) compared to the control group
(10%), whereas severe acute GvHD grades III-IV in the groups
were 8% vs 14%, respectively. These observations prompted us to
thoroughly study the effect of NAC on T cell mediated immunity
in vitro. We have found that low levels of NAC (0.4–3.2 mM) poten-
tiate T cell proliferation and upregualtion of activation markers in
response to alloantigens, whereas high concentrations (12.5–50
mM) are highly suppressive, which might explain the previously pub-
lished conflicting data. Furthermore, T cells that have been stimu-
lated in the presence of high concentrations of NAC (25 mM) in
a primary mixed lymphocyte reaction (MLR) respond more vigor-
ously when restimulated in a secondary MLR without NAC, com-
pared to control secondary MLR which had been cultured without
NAC during both stimulations. Preliminary data indicate that this
observation partly can be explained by that NAC render T cells
less apoptotic, and that T cells respond robustly when NAC has
been metabolized. To summarize, we have found that NAC has an
immunostimulatory effect on T cells under certain conditions,
both in vitro and in vivo. These observations might be of clinical im-
portance, as NAC potentially could be used as a therapeutic agent to
promote T cell mediated immunity in immunocompromized ASCT
patients with relapse of the underlying malignant disease.356
INTRA-ARTERIAL STEROIDS FOR SYSTEMIC STEROID RESISTANT GRAFT-
VS-HOST DISEASE
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